Dr. Gerald L. Andriole, the Robert K. Royce Distinguished Professor of Urologic Surgery and chief of the Division of Urologic Surgery, is a central member of the fellowship experience. Dr. Andriole is a member of the Siteman Cancer Center and has leadership roles in many national and international prostate research projects. Dr. Andriole serves as chairman of the Prostate Committee of the NCI-directed Prostate, Lung, Colorectal and Ovarian [PLCO] Cancer Screening Trial. He has a busy oncology practice focusing on the treatment of prostate cancer. Fellows work with Dr. Andriole in the operating room and collaborate on research projects during their fellowship.
Dr. Robert (Sherb) Figenshau, professor in the Division of Urology and director of Minimally Invasive Urology, assists in directing the minimally invasive surgical experience for fellows. He has a busy clinical practice focused on minimally invasive approaches to urologic oncology. In addition, he directs a large animal laboratory where fellows can investigate novel minimally invasive treatment approaches to urologic malignancies. Fellows work with Dr. Figenshau both clinically and in the laboratory
Dr. Robert L. Grubb, an assistant professor in the Division of Urology and a member of the Siteman Cancer Center, serves as assistant program director of the fellowship. He also has a busy clinical practice focused on urologic oncology including both minimally invasive and open approaches to all tumor types. He is actively involved in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Additionally, his laboratory is focusing on using MRI to image localized prostate cancer and markers of chemoresponsiveness in bladder cancer. Fellows work with Dr. Grubb in the clinical arena and have the opportunity to work with him on research projects.
| Dr. Sam Bhayani, as associate professor in the Division of Urology, is director of the Minimally Invasive Laboratory and co-director of the Robotic Program. He specializes in the treatment of prostate cancers and kidney cancers, tumors and masses in a minimally invasive fashion (laparoscopic and robotic).
Dr. Seth Strope, an assistant professor in the Division of Urology, has an active clinical practice that encompasses a wide spectrum of genitourinary cancers using open, laparoscopic and robotic surgical approaches. Dr. Strope, who earned an MPH degree in epidemiology at the University of Michigan, has research interests in epidemiology, outcomes and health services research on genitourinary cancer. His research uses large administrative databases including SEER, SEER-Medicare and HCUP data for these investigations. He serves as faculty in the Washington University Master of Population Health Sciences Program as well as in the Urologic Oncology Fellowship and Urology Residency Program.
Dr. Jeff Arbeit, professor and a member of the Siteman Cancer, is the scientific director of the Division of Urologic Surgery. Dr. Arbeit is an expert in mouse models of cancer and cancer genetics. His lab currently is focused on developing mouse models of prostate cancer and understanding the role of mTOR as a potential target for prostate cancer treatment. Fellows have the opportunity to work in Dr. Arbeit’s lab; however, he will provide basic science mentorship for the fellows whether they work in his laboratory or not.
Dr. Jeff Michalski, professor of radiation oncology, is an integral part of the fellow’s experience. Dr. Michalski’s practice focuses on the treatment of urologic cancers, primarily prostate cancer, but also on the bladder and testis. He is a leader in the field of urologic oncology having been the primary investigator for multiple Radiation Therapy Oncology Group (RTOG) trials investigating high-dose external beam irradiation (EBRT) and brachytherapy. Fellows rotate half a day per week with Dr. Michalski during their clinical year. They focus on both treatment (e.g., brachytherapy, EBRT) and patient selection (e.g., neoadjuvant hormone ablation, bladder preservation protocols).
Dr. Joel Picus, associate professor of medicine in the Division of Medical Oncology, also works with fellows. His practice focuses on the treatment of urologic cancers, including malignancies of the prostate, bladder, kidney and testis. He is a leader in the field of urologic oncology who has been the primary investigator for multiple institutional and national clinical trials. Fellows rotate half a day per week with Dr. Picus during their clinical year to become familiar with patient selection for chemotherapy and clinical chemotherapy trial design.